Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

Arch Neurol. 2003 Aug;60(8):1059-64. doi: 10.1001/archneur.60.8.1059.

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce dopaminergic neuron degeneration in animal models of Parkinson disease (PD). However, no epidemiological data have been available on NSAID use and the risk of PD.

Objective: To investigate prospectively whether the use of nonaspirin NSAIDs or aspirin is associated with decreased PD risk.

Design, settings, and participants: Prospective cohorts of 44 057 men and 98 845 women free of PD, stroke, or cancer (Health Professionals Follow-up Study, 1986-2000, and Nurses' Health Study, 1980-1998). Main Outcome Measure Newly diagnosed PD.

Results: We documented 415 incident PD cases (236 men and 179 women). Participants who reported regular use of nonaspirin NSAIDs at the beginning of the study had a lower risk of PD than nonregular users during the follow-up; the pooled multivariate relative risk was 0.55 (95% confidence interval, 0.32-0.96, P =.04). Compared with nonusers, a nonsignificantly lower risk of PD was also observed among men and women who took 2 or more tablets of aspirin per day (relative risk, 0.56; 95% confidence interval, 0.26-1.21).

Conclusion: These findings are consistent with the hypothesis that use of NSAIDs may delay or prevent the onset of PD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetaminophen / pharmacology
  • Adult
  • Aged
  • Analgesics, Non-Narcotic / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Aspirin / pharmacology
  • Cohort Studies
  • Confidence Intervals
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Parkinson Disease / drug therapy*
  • Prospective Studies
  • Risk Factors

Substances

  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents, Non-Steroidal
  • Acetaminophen
  • Aspirin